CD40-stimulated B lymphocytes pulsed with tumor antigens are effective antigen-presenting cells that can generate specific T cells - PubMed (original) (raw)
. 2003 Jun 1;63(11):2836-43.
Affiliations
- PMID: 12782589
CD40-stimulated B lymphocytes pulsed with tumor antigens are effective antigen-presenting cells that can generate specific T cells
Réjean Lapointe et al. Cancer Res. 2003.
Abstract
Although they are considered as antigen-presenting cells, the role of antigen-unspecific B lymphocytes in antigen presentation and T-lymphocyte stimulation remains controversial. In this paper, we tested the capacity of normal human peripheral activated B cells to stimulate T cells using melanoma antigens or melanoma cell lysates. B lymphocytes activated through CD40 ligation and then pulsed with tumor antigens efficiently processed and presented MHC class II-restricted peptides to specific CD4(+) T-cell clones. This suggests that CD40-activated B cells have the functional and molecular competence to present MHC class II epitopes when pulsed with exogenous antigens, thereby making them a relevant source of antigen-presenting cells to generate T cells. To test this hypothesis, CD40-activated B cells were pulsed with a lysate prepared from melanoma cells and used to stimulate peripheral autologous T cells. Interestingly, T cells specific to melanoma antigens were generated. Additional analysis of these T-cell clones revealed that they recognized MHC class II-restricted epitopes from tyrosinase, a known melanoma tumor antigen. The efficient antigen presentation by antigen-unspecific activated B cells was correlated with a down-regulation in the expression of HLA-DO, a B cell-specific protein known to interfere with HLA-DM function. Because HLA-DM is important in MHC class II peptide loading, the observed decrease in HLA-DO may partially explain the enhanced antigen presentation after B-cell activation. Results globally suggest that when they are properly activated, antigen-unspecific B-lymphocytes can present exogenous antigens by MHC class II molecules and stimulate peripheral antigen-specific T cells. Antigen presentation by activated B cells could be exploited for immunotherapy by allowing the in vitro generation of T cells specific against antigens expressed by tumors or viruses.
Comment in
- Correspondence re R. Lapointe et al., CD40-stimulated B lymphocytes pulsed with tumor antigens are effective antigen-presenting cells that can generate specific T cells. Cancer Res 2003;63:2836-43.
von Bergwelt-Baildon M, Schultze JL, Maecker B, Menezes I, Nadler LM. von Bergwelt-Baildon M, et al. Cancer Res. 2004 Jun 1;64(11):4055-6; author reply 4056-7. doi: 10.1158/0008-5472.CAN-03-3606. Cancer Res. 2004. PMID: 15173021 No abstract available.
Similar articles
- Induction of EBV-latent membrane protein 1-specific MHC class II-restricted T-cell responses against natural killer lymphoma cells.
Kobayashi H, Nagato T, Takahara M, Sato K, Kimura S, Aoki N, Azumi M, Tateno M, Harabuchi Y, Celis E. Kobayashi H, et al. Cancer Res. 2008 Feb 1;68(3):901-8. doi: 10.1158/0008-5472.CAN-07-3212. Cancer Res. 2008. PMID: 18245493 - NY-ESO-1 119-143 is a promiscuous major histocompatibility complex class II T-helper epitope recognized by Th1- and Th2-type tumor-reactive CD4+ T cells.
Zarour HM, Maillere B, Brusic V, Coval K, Williams E, Pouvelle-Moratille S, Castelli F, Land S, Bennouna J, Logan T, Kirkwood JM. Zarour HM, et al. Cancer Res. 2002 Jan 1;62(1):213-8. Cancer Res. 2002. PMID: 11782380 - Antigen-presenting cells and the selection of immunodominant epitopes.
Blum JS, Ma C, Kovats S. Blum JS, et al. Crit Rev Immunol. 1997;17(5-6):411-7. Crit Rev Immunol. 1997. PMID: 9419428 Review. - [MHC tetramers: tracking specific immunity].
Kosor E, Gagro A, Drazenović V, Kuzman I, Jeren T, Rakusić S, Rabatić S, Markotić A, Gotovac K, Sabioncello A, Cecuk E, Kerhin-Brkljacić V, Gjenero-Margan I, Kaić B, Mlinarić-Galinović G, Kastelan A, Dekaris D. Kosor E, et al. Acta Med Croatica. 2003;57(4):255-9. Acta Med Croatica. 2003. PMID: 14639858 Review. Croatian.
Cited by
- Role of B cells as antigen presenting cells.
Rastogi I, Jeon D, Moseman JE, Muralidhar A, Potluri HK, McNeel DG. Rastogi I, et al. Front Immunol. 2022 Sep 8;13:954936. doi: 10.3389/fimmu.2022.954936. eCollection 2022. Front Immunol. 2022. PMID: 36159874 Free PMC article. Review. - Design of CD40 agonists and their use in growing B cells for cancer immunotherapy.
Kornbluth RS, Stempniak M, Stone GW. Kornbluth RS, et al. Int Rev Immunol. 2012 Aug;31(4):279-88. doi: 10.3109/08830185.2012.703272. Int Rev Immunol. 2012. PMID: 22804572 Free PMC article. Review. - Spatial genomics reveals a high number and specific location of B cells in the pancreatic ductal adenocarcinoma microenvironment of long-term survivors.
Aziz HM, Saida L, de Koning W, Stubbs AP, Li Y, Sideras K, Palacios E, Feliu J, Mendiola M, van Eijck CHJ, Mustafa DAM. Aziz HM, et al. Front Immunol. 2023 Jan 4;13:995715. doi: 10.3389/fimmu.2022.995715. eCollection 2022. Front Immunol. 2023. PMID: 36685537 Free PMC article. - Enhancing T Cell Immune Responses by B Cell-based Therapeutic Vaccine Against Chronic Virus Infection.
Kim MK, Lee A, Hwang YK, Kang CY, Ha SJ. Kim MK, et al. Immune Netw. 2014 Aug;14(4):207-18. doi: 10.4110/in.2014.14.4.207. Epub 2014 Aug 22. Immune Netw. 2014. PMID: 25177253 Free PMC article. - In vivo sensitized and in vitro activated B cells mediate tumor regression in cancer adoptive immunotherapy.
Li Q, Teitz-Tennenbaum S, Donald EJ, Li M, Chang AE. Li Q, et al. J Immunol. 2009 Sep 1;183(5):3195-203. doi: 10.4049/jimmunol.0803773. Epub 2009 Aug 10. J Immunol. 2009. PMID: 19667089 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Other Literature Sources
Medical
Research Materials